- Home
- RILYP vs MRK Comparison
RILYP vs MRK Comparison
Compare RILYP & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RILYP | MRK |
|---|---|---|
| Founded | 1973 | 2000 |
| Country | United States | United States |
| Employees | 2056 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 268.7B |
| IPO Year | N/A | 1994 |
Fundamental Metrics
Financial Performance| Metric | RILYP | MRK |
|---|---|---|
| Price | $8.99 | $115.85 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $124.29 |
| AVG Volume (30 Days) | 15.4K | ★ 8.0M |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | ★ 7.03% | 2.93% |
| EPS Growth | N/A | ★ 8.01 |
| EPS | N/A | ★ 7.28 |
| Revenue | $854,383,000.00 | ★ $65,011,000,000.00 |
| Revenue This Year | N/A | $3.74 |
| Revenue Next Year | N/A | $5.47 |
| P/E Ratio | ★ N/A | $15.94 |
| Revenue Growth | N/A | ★ 1.31 |
| 52 Week Low | $1.75 | $75.40 |
| 52 Week High | $14.50 | $125.14 |
Technical Indicators
Market Signals| Indicator | RILYP | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 40.74 | 45.57 |
| Support Level | $8.70 | $113.82 |
| Resistance Level | $14.50 | $125.14 |
| Average True Range (ATR) | 0.87 | 2.78 |
| MACD | -0.12 | -1.04 |
| Stochastic Oscillator | 15.76 | 18.37 |
Price Performance
Historical ComparisonAbout RILYP B. Riley Financial Inc.
BRC Group Holdings Inc is a diversified holding company, including financial services, telecom, and retail, and investments in equity, debt and venture capital.
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).